Mercados españoles cerrados en 40 mins

Sage Therapeutics, Inc. (SAGE)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
18,80-0,25 (-1,29%)
A partir del 11:50AM EDT. Mercado abierto.

Sage Therapeutics, Inc.

215 First Street
Cambridge, MA 02142
United States
617 299 8380
https://www.sagerx.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo487

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Barry E. GreenePresident, CEO & Director1,29MN/A1963
Ms. Kimi E. Iguchi CPACFO & Treasurer665,37k144,99k1962
Ms. Anne Marie Cook Esq.Senior VP, General Counsel & Secretary711,6kN/A1962
Mr. Christopher BenecchiChief Business Officer703,76kN/A1972
Dr. Laura Gault M.D., Ph.D.Chief Medical Officer334,08kN/AN/A
Mr. Matt LasmanisChief Technology & Innovation OfficerN/AN/AN/A
Mr. Mike QuirkChief Scientific OfficerN/AN/AN/A
Ashley KaplowitzDirector of Investor RelationsN/AN/AN/A
Ms. Erin E. LancianiChief People & Experience OfficerN/AN/A1969
Dr. Amy Schacterle Ph.D.Senior Vice President of R&D Strategy and Business ManagementN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Sage Therapeutics, Inc., a día 1 de marzo de 2024, es 8. Las puntuaciones base son Auditoría: 7; Tablero: 7; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.